AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
AtriCure, Inc. (NASDAQ: ATRC) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $40.00 price target on the stock.
AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Canaccord Genuity Group Inc. from $53.00 to $61.00. They now have a "buy" rating on the stock.
AtriCure, Inc. (NASDAQ:ATRC) Shares Could Be 26% Below Their Intrinsic Value Estimate [Yahoo! Finance]
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference